Inogen (INGN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ea
Inogen's overall first-quarter 2025 results continue to gain from higher business-to-business sales.
Inogen, Inc. (NASDAQ:INGN ) Q1 2025 Earnings Conference Call May 7, 2025 5:00 PM ET Company Participants Ryan Peterson - Investor Relations Kevin Smith - President and CEO Mike Bourque - CFO Conferenc
Although the revenue and EPS for Inogen (INGN) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street e
Inogen (INGN) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.62 per share a year ago.
The medical device sector saw steady sales growth in the first quarter of 2025, supported by innovation in AI, wearables, and personalized care. However, earnings gains were more modest as global tari
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
GOLETA, Calif.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen To Present at 24th Annual Needham Virtual Healthcare Conference.
Although the revenue and EPS for Inogen (INGN) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Stree
Inogen, Inc.  INGN is well-poised for growth in the coming quarters, courtesy of high prospects in the portable oxygen concentrator (POC) space. The optimism, led by solid fourth-quarter 2024 perform
Inogen's new management and strategy are yielding results, with better-than-expected 2024 performance and a more stable base from which to keep growing the B2B business. Despite weak DTC sales, strong
Medical Technology company Inogen Inc INGN reported a fourth-quarter adjusted EPS loss of 24 cents, compared to a loss of 83 cents a year ago, beating the consensus loss of 61 cents.
Inogen's overall fourth-quarter 2024 results continue to gain from higher business-to-business sales.
Inogen, Inc. (NASDAQ:INGN ) Q4 2024 Earnings Conference Call February 25, 2025 5:00 PM ET Company Participants Ryan Peterson – Investor Relations Kevin Smith – President and Chief Executive Office
Inogen (INGN) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $1.14 per share a year ago.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE